NRXP
NRx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.49
+1.75%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +35.0%
- EBIT
- -40.3%
- EPS
- +68.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +2404.0%
- EBITDA
- -22.3%
- EPS
- -2.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -15.7%
- EBIT
- +17.7%
- Net income
- -13.9%
- EPS
- +43.9%
- Free cash flow
- -32.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026